TNF and neoplasm: This combination of immunotherapy retards tumor growth and prolongs the patient’s survival by rapidly inducing hemorrhagic necrosis dependent on tumor necrosis factor (TNF) production by tumor-associated myeloid cells followed by a CD8 T cell response required for tumor eradication (Yang et al., 2013).